Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Aaron P. Rapoport"'
Autor:
Jean A. Yared, Elizabeth Hutnick, Ashraf Badros, Mehmet H. Kocoglu, Nancy M. Hardy, Forat Lutfi, Søren M. Bentzen, Jonathan Siglin, Aaron P. Rapoport, Firas El Chaer, Carl Shanholtz, Kathleen Ruehle, Vivek Kesari, Noa G. Holtzman, Hao Xie, Haroon Ahmad, Saurabh Dahiya, Ali Bukhari, Natalie Gahres
Publikováno v:
Neuro Oncol
Background CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR-T) has emerged as effective for relapsed/refractory large B-cell lymphoma (R/R LBCL). The neurologic toxicity seen with CAR-T, referred to as immune effector cell–associat
Autor:
A. Badros, Dianna S. Howard, Barry R. Meisenberg, Donna E. Reece, David H. Vesole, Joanne Filicko-O'Hara, Jasleen K Randhawa, Neal Flomenberg, Parameswaran Hari, Aaron P. Rapoport, Gordon L. Phillips
Publikováno v:
Bone Marrow Transplantation. 54:293-299
The most common preparative regimen for autologous transplantation (ASCT) in myeloma (MM) consists of melphalan 200 mg/m2 (MEL 200). Higher doses of melphalan 220–260 mg/m2, although relatively well tolerated, have not shown significant improvement
Autor:
Ahmet Dogan, Mehmet Hakan Kocoglu, Sunita Philip, Ning Ma, Olga Goloubeva, Elizabeth Hyjek, Cameron Dell, Alexander M. Lesokhin, Aaron P. Rapoport, Emily Lederer, Ashraf Z. Badros, Zeba N. Singh, Todd Milliron
Publikováno v:
Blood. 130:1189-1197
Programmed death 1 (PD-1) receptor and its ligand (PD-L1) facilitate immune evasion in multiple myeloma (MM). We hypothesized that pembrolizumab, PD-1-antibody, can enhance antimyeloma cellular immunity generated by pomalidomide, leading to improved
Autor:
Michael R. Bishop, Parameswaran Venugopal, Aaron P. Rapoport, James Godfrey, Walter M. Stadler, Reem Karmali, Kenneth S. Cohen, Chadi Nabhan, Justin Kline, Theodore Karrison, Sonali M. Smith
Publikováno v:
Cancer. 125(11)
Background Dual translocation of MYC and BCL2 or the dual overexpression of these proteins in patients with aggressive B-cell lymphomas (termed double-hit lymphoma [DHL] and double-expressor lymphoma [DEL], respectively) have poor outcomes after chem
Autor:
Ashkan Emadi, E Binder, N C Porter, Madhurima Koka, Zeba N. Singh, Noa G. Holtzman, Aaron P. Rapoport, F El Chaer
Publikováno v:
Bone marrow transplantation. 52(11)
Durable remission with salvage decitabine and donor lymphocyte infusion (DLI) for relapsed early T-cell precursor ALL
Autor:
J. Joseph Melenhorst, Joseph A. Fraietta, Bruce L. Levine, Dan T. Vogl, Megan Davis, Carl H. June, Adam Waxman, Edward A. Stadtmauer, Don L. Siegel, Ehren K. Dancy, Alfred L. Garfall, Michael C. Milone, Adam D. Cohen, Aaron P. Rapoport
Publikováno v:
Blood. 132:1886-1886
Introduction: The optimal clinical setting and cell product characteristics for chimeric antigen receptor (CAR) T cell therapy in multiple myeloma (MM) are uncertain. In CLL patients treated with anti-CD19 CAR T cells (CART19), prevalence of an early
Autor:
Karen Chagin, Edward A. Stadtmauer, Trupti Trivedi, Frank Fang, Gwendolyn Binder-Scholl, Malini Iyengar, Thomas H. Faitg, Elliot Norry, Tom Holdich, Rafael G. Amado, Aaron P. Rapoport
Publikováno v:
Blood. 130:845-845
Background: NY-ESO-1 and LAGE-1a are cancer-testis antigens that are overexpressed in patients with multiple myeloma (MM), and the incidence of these antigens correlates with tumor proliferation and other high-risk features. Genetically engineered NY
Publikováno v:
Respirology Case Reports. 5:e00233
Multiple myeloma is a plasma cell dyscrasia accounting for 10% of haematologic malignancies. Lenalidomide is an immunomodulatory drug analogous to thalidomide that is approved for use in patients with myelodysplastic syndrome, and in combination with
Autor:
Sunita Philip, Ning Ma, Patricia Lesho, Ashlee Johnson, Olga Goloubeva, Mehmet H. Kocoglu, Elizabeth Hyjek, Alexander M. Lesokhin, Aaron P. Rapoport, Cameron Dell, Emily Lederer, Zeba N. Singh, Ashraf Badros
Publikováno v:
Blood. 128:490-490
BACKGROUND: Immunotherapy in MM is emerging as an effective modality in therapy of MM with the approval of several monoclonal antibodies and encouraging results for vaccines and T cell therapy. Programmed death 1 (PD-1) receptor and its ligand (PD-L1
Autor:
Adam M. Petrich, Aaron P. Rapoport, Bethany G. Sleckman, Sonali M. Smith, Walter M. Stadler, Kenneth S. Cohen, Justin Kline, Theodore Karrison, Sachdev P. Thomas, Krishna Rao, Sreenivasa Nattam
Publikováno v:
Blood. 128:4147-4147
Background: mTOR inhibitors, including temsirolimus (TEM), have demonstrated activity in patients (pts) with relapsed/refractory (rel/ref) lymphomas (J Clin Oncol 2010;28(31):4740). Lenalidomide (LEN) is an immunomodulatory agent with activity in a n